Metis Precision Medicine is a B-Corp that is dedicated to advancing scientific knowledge about cancer and developing new drugs based on precision medicine. Founded by Prof. P.

M. Comoglio and his team at the Candiolo Cancer Institute – IRCC, Metis possesses an extensive patent portfolio and is committed to making innovative treatments available to patients. Their lead product, hOA-DN30, is a highly potent anticancer drug.

This anti-MET antibody is fully humanized and single-armed, engineered to be both effective and virtually free of toxicity. Metis Precision Medicine goes beyond profit, adhering to the highest standards of purpose, responsibility, and transparency. Their mission is to maximize positive societal impact, benefiting the entire human race and the environment.

With a team of esteemed experts in oncology, research and development, medical advisory, and finance, Metis Precision Medicine is well-positioned to revolutionize cancer treatment. They are supported by the Club degli Investitori, an entrepreneurial association focused on investing in innovative businesses, and iAB Italian Angels for Biotech, an association of investors specializing in life sciences